Hengrui (恒瑞医药) A/H Listing: An Updated Comparison with Hansoh
Jiangsu Hengrui Medicine aims to raise around US$2bn in its H-share listing. In this note we provided an updated comparison with its close peer...
697 Views
Wuxi XDC Placement - Following Biologics Playbook, past Deals Have Been Mixed
WuXi AppTec (2359 HK) aims to raise around US$250m via selling around 3.5% stake in WuXi XDC Cayman (2268 HK). In this note, we talk about the deal...
586 Views
A/H Premiums and past A/H Listings Performance Data - Mixed Results but Size Matters
Given the slew of A/H offerings in the Hong Kong IPO pipeline, in this note, we talk about the overall A/H premiums currently.
785 Views
HLB Life Science (067630 KS): FDA Rejects Oncology Drug AGAIN; What Lies Ahead
HLB Life Science shares dropped 20% as group company Elevar Therapeutics faces setback with FDA rejecting new cancer drug application for...
520 Views
Hengrui (恒瑞医药) A/H Listing: A Worthy Comparison with Hansoh Pharma
China's Jiangsu Hengrui Medicine plans to raise $2bn in H-share listing. We did a worthy comparison between it and Hansoh Pharma.
891 Views